Renal Cell Carcinoma
Consorzio Oncotech is involved in clinical research for metastatic renal cell carcinoma and oligometastatic renal cell carcinoma, with a focus on treatment strategies for patients eligible for local and systemic cancer control.
- pembrolizumab in resectable metastatic kidney cancer
- nivolumab and ipilimumab sequencing
- axitinib intensification
The sponsor’s renal cancer portfolio centers on advanced disease management and therapeutic approaches for patients with limited metastatic burden.
Breast Cancer
The sponsor funds studies in metastatic triple-negative breast cancer and hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer, addressing both aggressive and endocrine-responsive disease settings.
- PD-L1 positive triple-negative breast cancer
- CDK4/6 inhibitor-resistant breast cancer
- locally advanced and metastatic disease
Research activity includes immunotherapy-based and endocrine-based treatment options for women with progressing breast cancer.
Immuno-Oncology
Clinical programs supported by the sponsor include immune checkpoint inhibitor strategies across solid tumors, with attention to combinations that target tumor progression and disease control.
- pembrolizumab
- atezolizumab
- nivolumab plus ipilimumab
These studies reflect interest in immunotherapy for both kidney and breast cancer indications.
Targeted and Endocrine Therapy
Consorzio Oncotech also supports research in targeted therapy and endocrine therapy, particularly in patients whose disease has progressed after prior treatment.
- palbociclib
- fulvestrant
- axitinib
This area includes treatment approaches for breast cancer after CDK4/6 inhibitor exposure and for renal cancer requiring continued systemic management.
